SGI invests $4.5M in Phase 3 trials of ColiFin for chronic infections
SPRIM Global Investments (SGI) has committed $4.5 million to initiate Spexis’ Phase 3 COPILOT clinical trial to test the antibiotic ColiFin in people with cystic fibrosis (CF) who have chronic Pseudomonas aeruginosa lung infections. The trial will test once or twice daily dosing of ColiFin (inhaled colistimethate sodium),…